

**Form 51-102F3**  
**MATERIAL CHANGE REPORT**

**Item 1. Name and Address of Reporting Issuer**

NervGen Pharma Corp. (“NervGen” or the “Company”)

112-970 Burrard Street  
Unit 1290  
Vancouver, BC V6Z 2R4

**Item 2. Date of Material Changes**

February 12, 2026

**Item 3. News Releases**

A news release announcing the material change was disseminated on February 12, 2026 through GlobeNewswire distribution network, and a copy was filed on NervGen’s SEDAR+ profile at [www.sedarplus.ca](http://www.sedarplus.ca).

**Item 4. Summary of Material Changes**

On February 12, 2026, the Company announced that Bill Adams will retire as Chief Financial Officer, effective March 15, 2026.

**Item 5. Full Description of Material Changes**

On February 12, 2026, the Company announced that Bill Adams will retire as Chief Financial Officer, effective March 15, 2026.

The Company has engaged an executive search firm to identify a successor, and Mr. Adams will continue in an advisory capacity following his retirement date to support the transition.

**Item 6. Reliance on subsection 7.1(2) of National Instrument 51-102**

Not applicable.

**Item 7. Omitted Information**

No information has been omitted on the basis that it is confidential information.

**Item 8. Executive Officer**

William Adams, Chief Financial Officer

112-970 Burrard Street  
Unit 1290  
Vancouver, BC V6Z 2R4

Item 9.

**Date of Report**

February 17, 2026.